© 2026 Nguza AI Social Earning Marketplace
Portuguese (Brazil)
Atualizações recentes
-
PIC/S GMP Annex 17 Explained: Parametric Release for Sterile Medicinal ProductsFor decades, proving the sterility of terminally sterilized pharmaceutical products relied on a traditional approach: standard finished product sterility testing. However, incubating sample units for 14 days can only confirm microbial contamination if it occurs in the test sample—it does not actively guarantee the sterility of the entire batch. Furthermore, traditional end-product testing...0 Comentários 0 Compartilhamentos 98 Visualizações 0 AnteriorFaça o login para curtir, compartilhar e comentar!
-
PIC/S Inspection Readiness: How to Identify and Close GMP Compliance Gaps Before an Inspector ArrivesIn the global pharmaceutical marketplace, expanding into new international territories is essential for growth. However, navigating the varying regulatory expectations of multiple health authorities can quickly become an operational minefield. This is where the Pharmaceutical Inspection Co-operation Scheme (PIC/S) plays a transformative role. By harmonizing Good Manufacturing Practice (GMP)...0 Comentários 0 Compartilhamentos 77 Visualizações 0 Anterior
-
PK-Stat Review for Clinical Trials: From Study Design to Regulatory-Ready PK DataIn modern drug development, generating clinical data is only half the battle. The true test of a successful trial lies in how rigorously that data is analyzed, interpreted, and presented to regulatory authorities. At the heart of pharmacokinetic and pharmacodynamic (PK/PD) evaluations are specialized PK-Stat (Pharmacokinetic-Statistical) reviews—a critical discipline that bridges clinical...0 Comentários 0 Compartilhamentos 84 Visualizações 0 Anterior
-
Environmental Risk Assessment (ERA) Services in Europe: Supporting Pharmaceutical Companies with Regulatory ComplianceFor pharmaceutical companies seeking marketing authorization in Europe, proving safety and efficacy is only part of the equation. Today, every submission to the European Medicines Agency (EMA) or national competent authorities must also demonstrate that the medicinal product does not pose an unacceptable environmental risk. What was once viewed as a secondary regulatory checkbox has evolved...0 Comentários 0 Compartilhamentos 69 Visualizações 0 Anterior
-
ICH Q12 and Pharmaceutical Lifecycle Management: What Companies Need to Know About Post-Approval ChangesNearly seven years after its finalization by the ICH Assembly in November 2019, ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management) has officially moved from a forward-looking conceptual framework to an operational regulatory expectation. With the FDA advancing its implementation, the EU clearing legal pathways through Regulation (EU) 2024/1701,...0 Comentários 0 Compartilhamentos 209 Visualizações 0 Anterior
-
0 Comentários 0 Compartilhamentos 86 Visualizações 0 Anterior
Mais stories